-45.7%
RDW vs GSK
+62.4%
-108.2%
-87.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -13.2% | -0.1% | -13.1% | -13.2% |
| 7D | -26.9% | -5.3% | -21.6% | -26.5% |
| 30D | -34.0% | -3.7% | -30.3% | -33.7% |
| 3M | -52.0% | -7.3% | -44.7% | -51.6% |
| 6M | -61.7% | -4.2% | -57.5% | -61.6% |
| YTD | -25.7% | +0.9% | -26.5% | -26.0% |
| 1Y | +11.7% | +7.3% | +4.4% | +10.4% |
| 3Y | +126.0% | +52.7% | +73.3% | +108.6% |
| 5Y | -43.1% | +40.1% | -83.2% | -48.9% |
| All | -45.7% | +62.4% | -108.2% | -52.4% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling